Polyrizon Ltd. (PLRZ) Stock Score, Valuation & Financial Research

Polyrizon Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PLRZ

Polyrizon Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 9.08. These figures are a research snapshot, not a buy or sell recommendation.

What Polyrizon Ltd. does

Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Polyrizon Ltd. is a pre-clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of proprietary intranasal hydrogel technologies, specifically its Capture and Contain (C&C) platform, which is intended to function as a biological mask to protect against viruses and allergens.

Products and services

  • The company develops intranasal hydrogel-based medical devices and protective solutions, including its proprietary Capture and Contain (C&C) technology and the Trap and Target (T&T) pre-clinical nasal delivery platform.

Brands and product families

  • Capture and Contain (C&C) — Proprietary hydrogel technology platform for nasal sprays. Source
  • Trap and Target (T&T) — Pre-clinical stage technology for nasal delivery of active pharmaceutical ingredients. Source

Business strengths to evaluate

  • Proprietary Capture and Contain (C&C) hydrogel technology platform Source

Business risks and research considerations

  • Development-stage company with no history of revenue or profitable operations Source
  • Substantial need for additional capital to fund research and development activities Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PLRZ financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 9.08
Market capitalization:
10.17M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -4.76M
Free cash flow:
USD -4.54M
Cash:
USD 8.41M
Total debt:
USD 0.00
EPS:
USD -4.22

What stands out

  • Free cash flow is USD -4.54M, negative for the stored period.
  • The balance sheet shows USD 8.41M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 8.41M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PLRZ

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PLRZ fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is PLRZ likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PLRZ to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PLRZ's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research PLRZ

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.